Key Takeaways

  • Jazz Pharmaceuticals has agreed to acquire a San Diego-based biotechnology company focused on developing treatments for genetic epilepsy, in a deal potentially worth just over $1.3 billion.
  • Under the deal terms, privately held Actio Biosciences will receive $820 million upfront, with up to $500 million in additional payments if its research programs meet certain regulatory and sales milestones. The company's lead drug candidate is being developed to treat a rare form of epilepsy caused by mutations in the KCNT1 gene.
  • The companies expect the transaction to close in the final quarter of this year. Concurrent with the closing, Actio will spin off a new private entity funded by existing investors, centered on another of its research programs—an ion channel inhibitor in early-stage testing for the treatment of Sandhoff disease, a rare neurological disorder. Jazz said it will hold a minority stake in the spun-off company, an investment focused on rare diseases that aligns "highly" with its long-term strategy.

Deep Dive

The acquisition of Actio reflects a notable uptick in acquisitions of venture-backed private biotech companies. A report from HSBC Innovation Bank counted 19 such deals in the first half of 2026, surpassing the full-year totals for each of the previous five years. During that six-month period, the median deal value reached $950 million, roughly three times the level seen in the early 2020s.

Through the Actio acquisition, Jazz will further expand its pipeline in one of its two core therapeutic areas—neuroscience. Its top-selling products include the sleep drug Xywav and Epidiolex, a cannabidiol-based treatment for two rare and severe childhood epilepsies. Jazz just postedits highest-ever quarterly total revenue, reaching $1.2 billion, up 16% year over year.

Jazz CEO Renee Gala said in a statement that the acquisition is "highly strategic," building on the success of the Epidiolex franchise and "deepening our leadership in rare and severe epilepsy."

Actio's core asset, codenamed ABS-1230, is a potential first-in-class treatment for KCNT1-related epilepsy. The disease currently has no approved therapies, and according to estimates cited by Jazz, affects about 2,500 patients in the United States. In more severe cases, patients may experience dozens or even hundreds of seizures per day. These seizures are often drug-resistant and can lead tosevere developmental delays and premature death。

ABS-1230 is designed to block overactive potassium channels that make brain circuits hyperexcitable and prone to seizures. Actio and Jazz said the drug recently produced "meaningful seizure reductions" in a proof-of-concept trial. The drug is currently being evaluated in astudy of about 55 participants, which could serve as the basis for a U.S. marketing application.

Actio said the drug also has the opportunity to be tested in more common genetic epilepsies.

Actio CEO David Goldstein said in the Monday statement that Jazz's development expertise and commercial scale should "ensure ABS-1230 reaches patients in the fastest and most efficient way possible."

Jazz plans to fund the transaction with existing cash and by drawing on its existing financing arrangements. The company reported cash, cash equivalents, and investments of $2.2 billion as of June 30. As of that date, its outstanding long-term debt principal balance was $4.4 billion. Additionally, it had $885 million in undrawn borrowing capacity under its revolving credit facility.

TD Cowen analyst Joseph Thome wrote in a note to clients that the acquisition adds "meaningful pipeline option value," though his team would like to see detailed patient-level data, a timeline for the release of key study results, and clarity on the regulatory submission package before "ascribing substantial value to the Actio drug."